Home         Forums  

Go Back   Marrowforums > Treatments > Transfusions and Iron Overload
Register FAQ Search Today's Posts Mark Forums Read

Transfusions and Iron Overload Blood and platelet transfusions, iron testing and treatments

Thread Tools Search this Thread
Old Mon Mar 24, 2008, 02:20 PM
Marlene Marlene is offline
Join Date: Oct 2006
Location: Springfield, VA
Posts: 1,360
Exjade and zinc levels

Has anyone experienced low blood serum zinc levels from Exjade? I've talked to Novartis and Accredo but they have no data on zinc being chelated with Exjade. Last fall we had John's zinc levels tested...both serum and red blood cell levels. The serum levels were below normal. Whether or not this can be attributed to the Exjade remains to be seen. However, I would be interested to know if anyone has experienced this? Low zinc is associated with poor wound healing, impaired immune funciton, hypogodnadism (men only), impaired development of bone/cartilage, skin issues and I'm sure much more.

What's also interesting is that John's 24 urine toxic metal panel shows that his aluminum levels have dropped....and this is due to the Exjade. In fact, his entire heavy metal panel has improved. So that's a good thing.

I found this on rxlist.com regarding Exjade....
Mechanism of Action/Pharmacodynamics
Exjade (deferasirox) is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain."

Other studies have not shown any decrease in copper or zinc. Since it's not clear to anyone, including Novartis, I think it's a good idea to have serum copper and zinc levels checked for anyone on Exjade for an extended period of time.

Marlene, wife to John DX w/SAA April 2002, Stable partial remission; Treated with High Dose Cytoxan, Johns Hopkins, June 2002. Final phlebotomy 11/2016. As of January 2017, FE is 233, HGB 11.7, WBC 5.1/ANC 4.0, Plts 90K.
Reply With Quote

Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Accepted into Campath Trial at NIH Greg H Drugs and Drug Treatments 279 Wed Aug 31, 2011 09:44 PM

All times are GMT -4. The time now is 04:56 PM.

Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2021, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright 2006-2020 Marrowforums.org